TMDX - NASDAQ
TransMedics Group, Inc.
$69.69
+3.2%TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
At a Glance
Live SnapshotTransMedics Group, Inc. Management Team
Dr. Tamer I. Khayal M.D.
Chief Commercial Officer
Compensation
$1,066,281
Mr. Gerardo Hernandez
Chief Financial Officer & Treasurer
Compensation
$214,619
Dr. Waleed H. Hassanein M.D.
Founder, President, Chief Executive Officer & Director
Compensation
$2,102,712
Mr. Nicholas Corcoran
Senior Vice President of Supply Chain & Operations
Compensation
$826,904
Mr. Anil Ranganath
Senior Vice President, General Counsel & Corporate Secretary
Compensation
$594,250
Ms. Miriam C. Provost Ph.D.
Vice President of Global Regulatory Affairs
Compensation
$535,930
TransMedics Group, Inc. Insider Positioning
During the last 12 months, insiders have purchased $2.77M and sold $4.57M worth of TMDX shares, resulting in $1.81M of net selling activity.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
14.9K
2.16M
-2.2M
-$2.16M
6-9 Months
8.8K
1.00M
13.1K
1.80M
-797K
-$797K
9-12 Months
15.0K
1.77M
4.8K
615.89K
+1.1M
+$1.15M
Top Buyers
Hassanein Waleed H
Director, Officer: President & Ceo
$2.77M
Top Sellers
Weill David
Director
$1.22M
Basile Edward M
Director
$1.06M
Hernandez Gerardo
Officer: Chief Financial Officer
$1.05M
Ranganath Anil P.
Officer: See Remarks
$652K
Corcoran Nicholas
Officer: See Remarks
$413K
Insider Activity Analysis
Net Insider Sentiment
Slightly bearish with $1.81M net selling. Selling modestly exceeds buying, which could be routine diversification rather than concern.
Buy/Sell Ratio
Moderately negative ratio. Selling is roughly double the buying, which may be routine or signal caution.
Insider Participation
5 insider sellers vs. 1 buyers. Widespread selling across multiple insiders may signal concerns.
SEC Filings
TMDX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 10, 2026 | May 20, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 10, 2025 | May 22, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 10, 2024 | May 23, 2024 | 2024 | |
DEF 14A DEF 14A N/A | April 12, 2023 | April 12, 2023 | ||
DEF 14A DEF 14A 2022 N/A | April 20, 2022 | June 01, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 16, 2021 | May 27, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 14, 2020 | June 04, 2020 | 2020 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.